Skip to content

Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression

Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052808
Enrollment
Unknown
Registered
2021-11-05
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behcet's disease

Interventions

Control group:No
Active period Behcet's disease(BD) group:No
Remission period BD group:No

Sponsors

Huadong Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Patients who fit the diagnosis of Behcet's disease (using the international classification criteria developed by the International Behcet Disease Study Group in 1990): (1) Recurrent oral ulcer: doctors observed or patients complained of aphthal ulcer or scar, recurrent >= 3 times within a year; (2) Recurrent genital ulcers: doctors have observed or patients have complained of aphthal ulcers, especially in men; (3) Eye diseases: pre and/or post pigmenitis, cell infiltration in vitreous on slit lamp examination, or retinal vasculitis; (4) Skin lesions: erythema nodosum lesions, pseudofolliculitis, purpuric papules, acne-like rash (without glucocorticoid); (5) Positive acupuncture reaction: a 20 ml sterile needle was inserted diagonally into the skin, and the result was determined by the doctor 24-48 hours later; Recurrent oral ulcers with 2 of the remaining 4 can be diagnosed as this disease; 2. Other symptoms that are closely related and helpful for diagnosis are arthralgia (arthritis).

Exclusion criteria

Exclusion criteria: 1. Other diseases (infections, tumors, and other autoimmune diseases) cause symptoms similar to behcet's disease; 2. Patients with severe heart disease, cardiac insufficiency, liver dysfunction, renal insufficiency, respiratory failure, malignant tumor, gastrointestinal bleeding, etc.; 3. Mental patients; 4. Unable to take medicine on time for other reasons; 5. Pregnant and lactating women; 6. Patients who are participating in other clinical trials; 7. Clinical trial subjects who the researchers believe are not suitable for other reasons; 8. Major organ lesions: subcutaneous embolic phlebitis, deep venous embolism, arterial embolism and/or aneurysm, central neuropathy, digestive ulcer, epididymitis, and family history.

Design outcomes

Primary

MeasureTime frame
Neutrophil extracellular traps (NETs);The expression of inflammatory factors;Infiltration of inflammatory cells;Macrophages-3;

Countries

China

Contacts

Public ContactShen Yan

Huadong Hospital of Fudan University

shenyan1212@sina.com+86 13585569294

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026